Meloxicam Stella

Meloxicam

Short-term symptomatic treatment of osteoarthrosis exacerbations. Symptomatic treatment of RA or ankylosing spondylitis.

Osteoarthrosis exacerbations 7.5 mg daily, may be increased to 15 mg daily in the absence of improvement. RA & ankylosing spondylitis 15 mg daily, may be reduced to 7.5 mg daily according to therapeutic response. Max: 15 mg daily. Elderly 7.5 mg daily for long-term treatment of RA & ankylosing spondylitis. Patient w/ increased risk for adverse reactions Start treatment w/ 7.5 mg daily. Dialysis patient w/ severe renal failure Max: 7.5 mg daily.

May be taken with or without food: May be taken w/ meals if GI discomfort occurs.

Hypersensitivity to meloxicam or substances w/ similar action eg, NSAIDs, aspirin. Patients who have developed signs of asthma, nasal polyps, angioneurotic oedema or urticaria following administration of aspirin or other NSAIDs. History of GI bleeding or perforation related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/haemorrhage. Active intestinal inflammatory disease (Crohn's disease, ulcerative colitis). GI, cerebrovascular or other bleeding disorders. Patients w/ severe heart failure. Treatment of peri-operative pain in CABG surgery setting. Severe hepatic impairment. Non-dialysed severe renal failure. 3rd trimester of pregnancy. Childn & adolescents <16 yr.

Do not exceed the recommended max daily dose in case of insufficient therapeutic effect. Not appropriate for the treatment of patients requiring relief from acute pain. Seek for any history of oesophagitis, gastritis &/or peptic ulcer to ensure their total cure before starting treatment. Associated w/ serious liver injury in rare cases. Increased risk of serious GI adverse events, including bleeding, ulceration, & perforation of the stomach or intestines; serious CV thrombotic events, MI, & stroke. Reports of fluid retention & oedema. Only treat patients w/ uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease, &/or cerebrovascular disease after careful consideration. Renal papillary necrosis & other renal injury during long-term administration. Renal toxicity in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Not recommended in patients w/ advanced renal disease. Very rare reports of serious skin reactions (some fatal), including exfoliative dermatitis, SJS & TEN. Discontinue treatment at the 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Reports of occasional increases in serum transaminase levels, serum bilirubin or other liver function parameters, serum creatinine & BUN, as well as other lab disturbances. May induce functional renal failure. Careful monitoring of diuresis & renal function is recommended at the beginning of treatment or after dose increase in patients w/ the following risk factors: elderly; concomitant treatments (eg, ACE inhibitors, AIIA, diuretics); hypovolemia; CHF; renal failure; nephrotic syndrome; lupus nephropathy; severe hepatic impairment (serum albumin <25 g/L or Child-Pugh score 10). May cause interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome in rare instances. Induction of Na, K & water retention; interference w/ natriuretic effects of diuretics; decreased antihypertensive effect of antihypertensive drugs. Regular monitoring of K values. May mask symptoms of underlying infectious disease. Avoid use w/ concomitant NSAIDs, including COX-2 selective inhibitors. May impair fertility. Not recommended in breastfeeding women & in women attempting to conceive. 1st & 2nd trimester of pregnancy. Elderly.

Dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea. Headache.

Increased toxicity w/ other NSAIDs, including ASA given at anti-inflammatory doses (≥1 g as single intake or ≥3 g as total daily amount). Increased risk of bleeding or GI ulceration w/ corticosteroids. Increased risk of bleeding w/ anticoagulants (eg, warfarin), heparin, thrombolytics & antiplatelet drugs. Increased risk of GI bleeding w/ SSRIs. Reduced effect of diuretics & other antihypertensive drugs. Further deterioration of renal function w/ ACE inhibitor or AIIA. Decreased antihypertensive effect of β-blockers. Enhanced nephrotoxicity of calcineurin inhibitors (eg, cyclosporine, tacrolimus). Decreased efficacy of IUD. Increased blood levels of lithium. Reduced tubular secretion of methotrexate. Accelerated elimination w/ cholestyramine.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AC06 - meloxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.

P₁S₁S₃